Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients

Purpose: We sought to examine the role of pretreatment systemic immune-inflammation index (SII) in hormone receptor-negative, human epidermal growth factor receptor 2+ (HER2+) breast cancer patients. Patients and methods: 155 HER2+ patients treated in our hospital from September 3, 2002, to Septembe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yi, Li, Wenqiang, Li, Ai-Jie, Su, Huichao, Yue, Jinbo, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489660/
https://www.ncbi.nlm.nih.gov/pubmed/31114357
http://dx.doi.org/10.2147/CMAR.S190335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489660/
https://www.ncbi.nlm.nih.gov/pubmed/31114357
http://dx.doi.org/10.2147/CMAR.S190335

Ejemplares similares